Floatz logo

Fludarabine

CD4+/CD56+ Hematodermic Neoplasm

Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the CD4+/CD56+ Hematodermic Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Methotrexate
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
Dexasone
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B
Cytarabine
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 47 →

Same molecule, other indications

Fludarabine is also rated in:

adult T-cell leukemia/lymphomaActive
BBB
Indicative · Phase 2
76 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative · Phase 2
76 / 100
View asset →
Fanconi anemiaActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →